Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma
Current Treatment Options in Oncology · 2024
DOI: 10.1007/s11864-024-01279-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Xiaoya He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, 443002, C…. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: Yichang Municipal Medical and Health Research Project Fund, Hubei Provincial Natural Science Foundation for Innovative Development Joint Fund Project, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University.
Abstract (Originalsprache)
OPINION STATEMENT: Melanoma, a highly invasive skin cancer resulting from melanocyte malignant transformation, is the third most common skin malignancy. Despite accounting for only 4% to 5% of all skin malignancies, it is responsible for 80% of skin cancer-related deaths. Targeted therapies and immune checkpoint inhibitors have improved survival rates, yet drug resistance remains a major challenge. In this review, I explore the latest research progress on melanoma drug resistance mechanisms and clinical treatment methods. This aims to provide insights for more effective treatment strategies and improve patient prognosis and quality of life. I also discuss potential strategies to overcome drug resistance based on the latest scientific findings, with a particular focus on the complex and multi-factorial drug resistance mechanisms of melanomas, including genetic mutations, epigenetic changes, and tumor microenvironment factors. Understanding these mechanisms is crucial for developing new drugs and combination therapies targeting drug-resistant tumors. Analyzing complex drug resistance pathways paves the way for personalized medical approaches, which is expected to provide enlightenment on breaking through drug resistance barriers and enhancing the effectiveness of melanoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
- The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China.
- The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China. zjqyhll@163.com.
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, 443002, China. xiao-tan@ctgu.edu.cn.
- The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China. xiao-tan@ctgu.edu.cn.
Förderung
- Yichang Municipal Medical and Health Research Project Fund
- Hubei Provincial Natural Science Foundation for Innovative Development Joint Fund Project
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University
- Applied Natural Science Fund of China Three Gorges University
Zitieren
APA
He, X., Deng, H., Liu, W., Hu, L., & Tan, X. (2024). Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01279-0
Vancouver
He X, Deng H, Liu W, Hu L, Tan X. Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01279-0
BibTeX
@article{He2024,
author = {He, Xiaoya and Deng, Hao and Liu, Wei and Hu, Liling and Tan, Xiao},
title = {Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma},
journal = {Current Treatment Options in Oncology},
year = {2024},
doi = {10.1007/s11864-024-01279-0}
}
EUVIMED